Skip to Main Content

Melanoma & Skin Cancer Center

The UCSF Melanoma and Skin Cancer Program provides specialized care for patients with all stages of melanoma, from early-stage growths to advanced metastatic cancer, as well as for patients who are healthy but at higher risk of the disease due to family history, genetic mutations or having many abnormal moles. We also care for patients with other types of skin cancer, including squamous cell, basal cell and Merkel cell carcinomas.

Our program is part of the UCSF Helen Diller Family Comprehensive Cancer Center, designated a comprehensive cancer center by the National Cancer Institute. This designation recognizes centers that provide full-spectrum, state-of-the-art cancer care.

Our team

Our skin cancer program brings together doctors from many specialties. Working collaboratively, they ensure our patients receive complete care that includes access to an array of treatment options. Our world-renowned team has the following types of subspecialists:

  • Medical dermatologists – who diagnose and treat a range of skin conditions
  • Surgical dermatologists – who provide surgical treatment for skin conditions
  • Dermatopathologists – experts in identifying cancers through microscopic examination of samples
  • Medical oncologists – experts in treating cancer with chemotherapy, immunotherapy and other therapies
  • Radiation oncologists – specialists in the various radiation therapies used to treat cancer
  • Surgical oncologists – specialists in surgical treatment of cancer
  • Otolaryngologists/head and neck surgeons – specialists in surgically treating head and neck cancers
  • Reconstructive surgeons – who perform procedures to repair and reshape damaged parts of the face or body

Also on our team are nurses and nurse practitioners, genetic counselors, psycho-oncologists, social workers, nutritionists and exercise counselors. All have special training in cancer care, including how to support and educate patients and their families.

Diagnosis and treatment

Our program emphasizes early diagnosis, because the earlier a skin cancer is detected, the greater the likelihood of successful treatment. We perform skin exams using dermatoscopes, handheld instruments that help us to distinguish cancerous lesions from noncancerous lesions with greater accuracy than eyes alone. We may also use digital dermoscopic photography (taking images with the dermatoscope) to closely track suspicious lesions over time.

We offer the full range of treatment options, including surgery, chemotherapy, radiation therapy and immunotherapy. When possible, we target the patient's specific cancer. Our dermatopathologists test melanomas for certain genetic mutations – such as BRAF, NRAS, KIT, GNAQ and GNA11 – to help us determine the most effective treatment for an individual patient. Our program holds a weekly tumor board meeting that allows multiple specialists to discuss complex cases and reach consensus on treatment recommendations.

Research and clinical trials

Our experts are leading clinical trials to evaluate some of the most innovative and promising new treatments for melanoma and other aggressive skin cancers. Interested patients may have the opportunity to participate.

Learn more about clinical trials and how they work.

Our locations

Expand Map

    Patient education

    Melanoma Patient Symposium 2023

    Learn by watching UCSF experts discuss the latest developments in melanoma research and treatment.

    Melanoma Patient Symposium 2022

    Watch last year’s symposium to learn about melanoma research developments in 2022.

    Decorative Caduceus

    VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti...

    Time from the date of randomization to death due to any cause

    Recruiting

    Decorative Caduceus

    Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma

    PFS is defined as the proportion of participants alive without progression of disease from the first day of radiotherapy to progression or death by any cause, whichever occurs first, assessed up to 2 years after the last day of ra...

    Recruiting

    Decorative Caduceus

    Study of RP1 Monotherapy and RP1 in Combination With Nivolumab

    Percentage of subjects with adverse events (AEs)

    Recruiting

    Decorative Caduceus

    A Phase 1B/2 Study of RP1 in Solid Organ Transplant Patients With Advanced Cutaneous Malignanci...

    Assess the safety and tolerability of single-agent RP1 in solid organ transplant patients with cutaneous malignancies by incidence of subjects with treatment-emergent adverse events

    Recruiting

    Decorative Caduceus

    A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recur...

    Recruiting

    Decorative Caduceus

    Fatigue and Molecular Mechanisms in Cancer Patients Receiving CCRT

    Association between phenotypic characteristics and initial levels and trajectories of CRF severity will be assessed using a hierarchical linear model (HLM) approach.

    Recruiting

    Decorative Caduceus

    Nisin in Oral Cavity Squamous Cell Carcinoma (OCSCC)

    Dose-limiting toxicities (DLTs) are defined in Section 5.2.3. DLT determination will assess adverse events (AEs) graded according to CTCAE v5.0, including findings on physical exam, vital signs, laboratory testing, and spontaneous...

    Recruiting

    Decorative Caduceus

    Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma

    Defined as complete response (CR) or partial response (PR) by Response Evaluation Criteria in Solid Tumors (RECIST v1.1). The ORR at stages 1 and 2 will be estimated using the method of Whitehead, and the p-values for testing the ...

    Recruiting

    Decorative Caduceus

    Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies

    To identify dose limiting toxicities [DLT] with GIM-122

    Recruiting

    Decorative Caduceus

    Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma

    The investigators will identify the genes predictive of response to anti-PD-1 therapy by testing for significant associations across expression rates of each gene and response/resistance, within a hurdle-Gaussian mixed-effect fram...

    Recruiting

    Rankings & achievements

    • U S  News and World Report badge recognizing UCSF as part of its 2024-2025 Honor Roll

      Among the top hospitals in the nation

    • Best in Northern California and No. 7 in the nation for cancer care

    • 600-2x

      melanoma patients seen each year

    Accreditations & memberships

    • National Cancer Institute

      The National Cancer Institute has designated UCSF a comprehensive cancer center, its highest ranking. This designation is awarded to centers that demonstrate scientific excellence and the ability to conduct cancer research across many disciplines.

    • Commission on Cancer

      UCSF's cancer programs have been accredited by the American College of Surgeons' Commission on Cancer (CoC) since 1933. The CoC is a consortium of groups dedicated to improving cancer patients' survival and quality of life via research, education and better medical care.

    • National Comprehensive Cancer Network

      UCSF is a member of the National Comprehensive Cancer Network, an alliance of the world’s top cancer centers. The network brings together leaders in treatment and research to improve the quality, effectiveness and efficiency of cancer care.

    Support services

    Preparing for your appointment

    What to Bring

    • Photo I.D.
    • Health insurance card
    • Insurance authorization, if required
    • Doctor's referral, if required
    • Recent test results related to your condition
    • List of your medications, including dosages, plus any you're allergic to
    • List of questions you may have
    • Device or paper for taking notes

    Related clinics

    Our research initiatives

    • UCSF-Helen-Diller-Family-Comprehensive-Cancer-Center-Research-2x

      UCSF Helen Diller Family Comprehensive Cancer Center Research

      UCSF is home to a range of research initiatives aimed at improving outcomes for cancer patients everywhere. This includes research on topics such as immunotherapy, BRCA mutations and molecular diagnostic testing.

    Can't find what you're looking for?

    UCSF Help Center

    (888) 689-8273

    Share